Invitrogen Sues Oxford Biomedical, Vanderbilt Over Patent Licensing Deal | GenomeWeb
NEW YORK (GenomeWeb News) – Invitrogen filed a suit this week against Oxford Biomedical Research and co-defendant Vanderbilt University regarding a patent licensing agreement entered into in 1996 between the defendants and PanVera, a firm that Invitrogen purchased in 2003 for $95 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.